Induction of Apoptosis and Effect on CD20+ Cell Numbers Using Rituximab on Autologous Peripheral Blood Stem Cell Harvests from Patients with B Cell Lymphomas

Stem Cells and Development

Volumn 13, Issue 2, 2004, Pages 193-196

  Borbolla Escoboza, Jose R ^a   Leon, Maria I ^a   Collados, Maria T ^a   Baez, Enrique ^b   Baltasar, Severiano ^b   Hernández, Roberto ^b   Rojas, Julio C ^a  

^a SCHOOL OF ENGINEERING AND SCIENCES   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; FAS ANTIGEN; GLUCONATE CALCIUM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; LYMPHOMA; PRIORITY JOURNAL; STEM CELL MOBILIZATION; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD19; ANTIGENS, CD20; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOOD TRANSFUSION, AUTOLOGOUS; BONE MARROW PURGING; CELL COUNT; CELL SEPARATION; HEMATOPOIETIC STEM CELLS; HUMANS; LYMPHOMA, B-CELL;

EID: 2342597772     PISSN: 15473287     EISSN: None     Source Type: Journal    
DOI: 10.1089/154732804323046792     Document Type: Article

References (16)

1. Spellberg B and GJ Schiller. (1999). Autologous bone marrow transplantation in acute leukemia. Hematol Oncol Clin N Am 13:919-938.
2. Sanz MA, J de la Rubia, S Bonanad, E Barragan, A Sempere, G Martin, JA Martinez, C Jimenez, J Cervera, P Bolufer and GF Sanz. (1998). Prolonged molecular remission after PML/RAR alpha-positive autologous peripheral blood stem cell transplantation in acute promyelocytic leukemia: Is relevant pretransplant minimal residual disease in the graft? Leukemia 12:992-995.
3. Meloni G, D Diverio, M Vignetti, G Avvisati, S Capria, MC Petti, F Mandelli and F Lo Coco. (1997). Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: Prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene. Blood 90:1321-1325.
4. Amadori S, AM Testi, M Arico, A Comelli, M Giuliano, E Madon, G Masera, R Rondelli, L Zanesco and F Mandelli. (1993). Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group. J Clin Oncol 11:1046-1050.
5. Magni M, M Di Nicola, L Devizzi, P Patteucci, F Lombardi, L Gandola, F Ravagnani, R Giardini, G Dastoli, C Tarella, A Pileri, G Bonadonna and AM Gianni. (2000). Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 96:864-869.
6. Lazzarino M, L Arcaini, P Bernasconi, EP Alessandrino, L Gargantini, R Cairoli, E Orlandi, C Astori, E Brusamolino, G Pagnucco, AA Colombo, S Calatroni, I Iacona, MB Regazzi and E Morra. (2002). A sequence of immuno-chemotherapy with rituximab, movilization of in vivo purged stem cells, high dose chemotherapy and autotransplant is an effective and non-toxic treatment for advance follicular and mantle cell lymphoma. Br J Haematol 116:229-235.
7. Hess G, T Flohr and HG Derigs. (2002). Rituximab as in vivo purging agent in autologous stem cell transplantation for relapsed B-NHL. Ann Hematol 81:S54-S55.
8. Schmitz N. (2001). Rituximab in autologous stem cell transplantation for follicular lymphoma. Anticancer Drugs 12:S21-S24.
9. Van der Kolk LE, AJ Grillo-López, JW Baars, CE Hack and HJ Van Oers. (2001). Complement activation plays a key role in the side effects of rituximab treatment. B J Haematol 115:807-811.
10. Badros A, B Barlogie, E Siegel, M Cottler-Fox, M Zangari, A Fassas, C Morris, E Anaissie, F Van Rhee and G Tricot. (2002). Improved outcome of allogenic transplantation in high-risk multiple myeloma patients after non-myeloablative conditioning. J Clin Oncol 20:1295-1303.
11. Flinn IW, PV O'Donell, A Goodrich, G Vogelsang, R Abrams, S Noga, D Marcellus, M Borowitz, R Jones and RF Ambinder. (2000). Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 6:628-632.
12. Joyce RM, CN Kraser, JC Tetrealt, N Giallombardo, D McDermott, J Levine, T Umiel, M Regan, D Hurley, L Uhl and D Avigan. (2001). Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B-cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant. Eur J Haematol 64:S56-S62.
13. Buckstein R, K Imrie, D Spaner, A Potichnyj, JB Robinson, S Nanji, N Pennel, M Reis, P Pinkerton, I Dube, K Hewitt and NL Berinstein. (1999). Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Semin Oncol 26: S115-S122.
14. Voso MT, G Pantel, M Weis, P Schmidt, S Martin, M Moos, AD Ho, R Haas and S Hohaus. (2000). In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol 109:729-735.
15. Kondo E, T Yoshino, I Yamadori, Y Matsuo, N Kawasaki, J Minowada and T Akagi. (1994). Expression of Bcl-2 protein and Fas antigen in non-Hodgkin's lymphomas. Am J Pathol 145:330-337.
16. Sweetenham J, K Hieke, M Kerrigan, P Howard, PE Smart, AM McIntyre and S Townshed. (1999). Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgin's lymphoma in the UK. B J Haematol 106:47-54.